Herein, we compared and analyzed the efficacy, safety, and long‐term follow‐up of humanized anti‐BCMA CAR‐T cell therapy in R/R MM patients with EM‐E, EM‐B, and without EMD. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.